Shares in Senseonics (NYSE:SENS) fell today after the diabetes-focused device maker posted first-quarter results that missed the consensus forecast on Wall Street.
The Germantown, Md.-based company cited positive early feedback on the March launch of its Eversense Bridge Program, which is designed to improve patient access to the company’s Eversense continuous glucose monitoring system.
Senseonics reported losses of -$29.4 million, or -17¢ per share, on sales of $3.4 million for the three months ended March 31, for a bottom-line loss of -32% on sales growth of 16.9% compared with Q1 2018.
Get the full story on our sister site, Drug Delivery Business.